Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of tacrolimus and i.v.[intravenous] -immunoglobulins in Rasmussen encephalitis with start of treatment in the acute disease stage. prospective, randomised, open parallel group study

X
Trial Profile

Efficacy of tacrolimus and i.v.[intravenous] -immunoglobulins in Rasmussen encephalitis with start of treatment in the acute disease stage. prospective, randomised, open parallel group study

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Apr 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary) ; Tacrolimus (Primary)
  • Indications Encephalitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Dec 2008 Planned number of patients identified as 16 from ClinicalTrials.gov.
    • 01 Dec 2008 Planned end date identified as 1 Jul 2010 from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top